Edition:
United States

Juno Therapeutics Inc (JUNO.OQ)

JUNO.OQ on NASDAQ Stock Exchange Global Select Market

44.17USD
14 Dec 2017
Change (% chg)

$-3.24 (-6.83%)
Prev Close
$47.41
Open
$47.60
Day's High
$48.62
Day's Low
$43.78
Volume
1,030,384
Avg. Vol
733,175
52-wk High
$63.33
52-wk Low
$17.52

Latest Key Developments (Source: Significant Developments)

Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center
Wednesday, 6 Dec 2017 09:00am EST 

Dec 6 (Reuters) - Juno Therapeutics Inc ::JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION.JUNO THERAPEUTICS - THREE LICENSE DEALS TO ADVANCE PROGRAM IN MULTIPLE MYELOMA USING GAMMA SECRETASE INHIBITORS WITH BCMA-DIRECTED CAR T CELLS.JUNO THERAPEUTICS INC - THROUGH ITS AGREEMENT WITH ELI LILLY AND COMPANY, JUNO WILL ACQUIRE A LICENSE TO GSI KNOWN AS LY3039478.JUNO THERAPEUTICS- CO TO ALSO GAIN RIGHTS TO INTELLECTUAL PROPERTY WITHIN FIELD OF COMBINATIONS OF GSIS, BCMA-DIRECTED ENGINEERED T CELLS IN OTHER DEALS.JUNO THERAPEUTICS INC - NO OTHER TERMS FROM THESE THREE TRANSACTIONS WERE DISCLOSED.  Full Article

Juno Therapeutics reports Q3 adjusted loss per share ‍$0.73​
Wednesday, 1 Nov 2017 04:05pm EDT 

Nov 1 (Reuters) - Juno Therapeutics Inc :Juno Therapeutics reports third quarter 2017 financial results.Juno Therapeutics Inc - qtrly ‍revenue $44.8 million versus $20.8 million​.Juno Therapeutics Inc - qtrly loss per share ‍$1.12​.Juno Therapeutics Inc - qtrly adjusted loss per share ‍$0.73​.Juno Therapeutics Inc - ‍expects to be in lower half of 2017 cash burn guidance​.Q3 earnings per share view $-0.80, revenue view $16.2 million -- Thomson Reuters I/B/E/S.  Full Article

Juno Therapeutics and Trianni sign licensing agreement for use of Trianni Transgenic Mouse platform
Wednesday, 18 Oct 2017 08:00am EDT 

Oct 18 (Reuters) - Juno Therapeutics Inc : :Trianni and Juno Therapeutics sign licensing agreement for use of Trianni Transgenic Mouse platform.Juno - to use Trianni Mouse with its single cell sequencing technology to identify fully-human binders for conversion to chimeric antigen receptors.Juno Therapeutics Inc - ‍no financial details were disclosed​.  Full Article

Juno Therapeutics files for offering of common stock aggregate offering price of $225 mln - SEC Filing‍​
Wednesday, 20 Sep 2017 04:17pm EDT 

Sept 20 (Reuters) - Juno Therapeutics Inc :Juno Therapeutics Inc - Files for offering of common stock; aggregate offering price of $225 million - SEC Filing‍​.  Full Article

Juno Therapeutics qtrly ‍loss per share $0.96
Thursday, 3 Aug 2017 04:05pm EDT 

Aug 3 (Reuters) - Juno Therapeutics Inc JUNO.O:Juno Therapeutics reports second quarter 2017 financial results.Juno Therapeutics Inc- ‍revenue for three months ended June 30, 2017 was $21.3 million compared to $27.6 million​.Qtrly ‍loss per share $0.96; qtrly adjusted loss per share $0.74​.Juno Therapeutics Inc- Juno reaffirms 2017 cash burn​.Juno Therapeutics Inc- ‍2017 operating burn estimated to be between $245 million and $275 million​.Q2 earnings per share view $-0.72, revenue view $15.8 million -- Thomson Reuters I/B/E/S.  Full Article

Juno Therapeutics says court decides it lacks jurisdiction over Kite Pharma lawsuit
Wednesday, 14 Jun 2017 09:00am EDT 

June 14 (Reuters) - Juno Therapeutics Inc ::Court decides it lacks jurisdiction before FDA approval occurs.Juno Therapeutics - U.S. District Court for district of Delaware decided it lacked jurisdiction at this time over a lawsuit filed against Kite Pharma.Juno Therapeutics - court cited absence of evidence that FDA approval of Kite's axicabtagene ciloleucel "is expected on defendant's BLA in immediate future.  Full Article

Juno Therapeutics reports Q1 loss per share $0.79
Thursday, 4 May 2017 04:05pm EDT 

May 4 (Reuters) - Juno Therapeutics Inc :Juno Therapeutics reports first quarter 2017 financial results.Q1 loss per share $0.79.Juno Therapeutics Inc - Revenue for three months ended March 31, 2017 and 2016 was $19.3 million and $9.8 million.Q1 earnings per share view $-0.71 -- Thomson Reuters I/B/E/S.Juno Therapeutics Inc - Reaffirms 2017 cash burn of between $270 million and $300 million.Juno Therapeutics Inc - Capital expenditures, net of tenant improvement allowances, estimated to be between $22 million and $27 million for FY.  Full Article

Juno Therapeutics reports qtrly net loss per share $0.51
Wednesday, 1 Mar 2017 04:05pm EST 

Juno Therapeutics Inc : Juno Therapeutics reports fourth quarter and 2016 financial results . Juno Therapeutics Inc - 2017 cash burn guidance of $270 million to $300 million . Juno Therapeutics Inc sees 2017 capital expenditures estimated to be between $22 million and $27 million . Juno Therapeutics Inc sees 2017 operating burn estimated to be between $245 million and $275 million . Juno Therapeutics Inc qtrly net loss per share $0.51 . Juno Therapeutics Inc qtrly revenue $21.2 million versus $ 4.2 million . Q4 earnings per share view $-0.61, revenue view $14.6 million -- Thomson Reuters I/B/E/S . Juno Therapeutics Inc qtrly net loss per share non-gaap $0.65 .Says "discontinuing development of jcar015 in r/r adult all to focus on defined cell product in this setting".  Full Article

Vanguard Group reports 5.52 pct passive stake in Juno Therapeutics as of Dec. 31, 2016
Friday, 10 Feb 2017 09:45am EST 

Juno Therapeutics Inc :Vanguard Group Inc reports 5.52 percent passive stake in Juno Therapeutics Inc as of Dec. 31, 2016 - sec filing.  Full Article

Juno Therapeutics highlights progress with best-in-class strategy in B-cell Malignancies at ASH
Tuesday, 6 Dec 2016 04:00pm EST 

Juno Therapeutics Inc : Plans to study JCAR014 in combination with ibrutinib in CLL are underway, with a cohort expected to begin enrollment in early 2017. . Juno Therapeutics highlights progress with best-in-class strategy in B-cell Malignancies at ASH .Juno intends to initiate a pivotal trial in U.S. in patients with r/r DLBCL in 2017..  Full Article

BRIEF-Juno Therapeutics Signs Licensing Agreements With Lilly, Oncotracker, And Fred Hutchinson Cancer Research Center

* JUNO THERAPEUTICS SIGNS LICENSING AGREEMENTS WITH LILLY, ONCOTRACKER, AND FRED HUTCHINSON CANCER RESEARCH CENTER TO ADVANCE ITS BCMA-DIRECTED ENGINEERED T CELL PROGRAM IN MULTIPLE MYELOMA WITH GAMMA SECRETASE INHIBITION